Cart
sales@molnova.com
Burfiralimab
CAS No. 2460809-80-5
Burfiralimab( —— )
Catalog No. M36776 CAS No. 2460809-80-5
Burfiralimab (hzVSF-v13) is a monoclonal immunoglobulin (IgG4) targeted against waveform proteins, exhibiting anti-HBV properties and potential applications in rheumatoid arthritis research.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 299 | Get Quote |
|
| 5MG | 471 | Get Quote |
|
| 10MG | 708 | Get Quote |
|
| 25MG | 1030 | Get Quote |
|
| 50MG | 1371 | Get Quote |
|
| 100MG | 1782 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBurfiralimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionBurfiralimab (hzVSF-v13) is a monoclonal immunoglobulin (IgG4) targeted against waveform proteins, exhibiting anti-HBV properties and potential applications in rheumatoid arthritis research.
-
DescriptionBurfiralimab (hzVSF-v13) is a monoclonal IgG4 antibody against vimentin expressed on the surface of virus-infected cells, with broad-spectrum antiviral activity and anti-inflammatory effects against virus-induced inflammation. Burfiralimab can be used in severe COVID-19 studies.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMicrobiology/Virology
-
TargetHBV
-
RecptorHBV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2460809-80-5
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Prasenohadi Prasenohadi, et al. Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19. J Clin Med. 2022 May 24;11(11):2961.?
molnova catalog
related products
-
Entecavir
Entecavir(BMS200475; SQ34676) is a guanosine analogue that inhibits reverse transcription, DNA replication and transcription in the viral replication process; oral antiHBV drug.
-
DVR-01
DVR-01 is an HBV capsid inhibitor and can be used in studies about the treatment of Hepatitis B virus (HBV) infection and related conditions.
-
AB-423
AB-423 is a novel potent, class II HBV capsid inhibitor that shows potent inhibition of HBV replication with EC50 of 0.08-0.27 uM, with no significant cytotoxicity (CC50>10 uM).
